MetaCap

Sanara MedTech Inc. (SMTI)

NASDAQ: SMTIHealth CareIndustrial SpecialtiesUSD

32.55-0.12 (-0.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SMTI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$298.90M
EPS (TTM)
-$0.28
52-week range
16.05 – 35.52
Day range
32.32 – 32.90
Volume / Avg
51.19K / 170.59K
Beta
—

52-week range

$16.05$35.52

SMTI stock today

On Nov 20, SMTI ended the session at $32.55, shedding $0.12 (0.37%), versus the S&P 500's 3.70% decline. Trading was light, with 51.19K shares changing hands, about 30% of the average daily volume. Shares are 8.4% below their 52-week high of $35.52, set on Oct 15, 2026 and 102.8% above the 52-week low of $16.05, near the top of the past year's range.

SMTI is up 39.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 67.1%. Sanara MedTech has posted a net loss over the last twelve months (EPS of -$0.28), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sanara MedTech

Company profile

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial and full-thickness wounds, as well as first and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement.

Industry
Industrial Specialties
CEO
Mr. Seth D. Yon
Headquarters
Fort Worth, TX
Employees
108

Financial highlights

Full financials

In fiscal 2025, Sanara MedTech generated $103.1 million in revenue, up 19.0% from fiscal 2024, its 7th consecutive year of revenue growth. Sanara MedTech reported a net loss of $37.6 million, compared with a loss of $9.7 million a year earlier. Gross margin was 92.7% (up from 90.6%) and operating margin 7.1%.

Sanara MedTech annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$103.12M$86.67M$64.99M$45.84M$24.14M
Growth+18.97%+33.36%+41.77%+89.87%+54.90%
Net income$-37.56M$-9.66M$-4.30M$-7.94M$-7.92M
EPS (diluted)$-4.36$-1.14$-0.52$-1.00$-1.08

Analyst forecast

Forecast

Consensus (3 analysts)

hold

Avg. price target

$35.00+7.53%

  • Strong buy 0
  • Buy 0
  • Hold 3
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.12 vs $0.06
Surprise
+100.00%

SMTI news

All SMTI news

Sanara MedTech peers

Health Care sector
SMTI peer companies
CompanyPrice% ChgMarket capCompare
MECMayville Engineering Company Inc.11.65-8.70%$297.09Mvs SMTI
ASLEAerSale Corporation4.93-1.00%$235.31Mvs SMTI
OFLXOmega Flex Inc.21.15-2.08%$213.49Mvs SMTI
HDSNHudson Technologies Inc.3.91-4.17%$164.57Mvs SMTI
AMROAmaero Inc.5.80+3.57%$160.76Mvs SMTI
INGNInogen Inc5.30-2.21%$137.81Mvs SMTI
BOOMDMC Global Inc.6.70-6.94%$137.62Mvs SMTI
AVRAnteris Technologies Global Corp.4.99-1.96%$486.49Mvs SMTI

Indexes, lists and sector

Sanara MedTech stock FAQ

What is Sanara MedTech's stock price today?

SMTI last traded at $32.55 as of Nov 20, 4:00 PM EST, down 0.37% on the day. Prices are delayed at least 15 minutes.

Does Sanara MedTech pay a dividend?

No. Sanara MedTech does not currently pay a regular cash dividend.

Who is Sanara MedTech's CEO?

Mr. Seth D. Yon is the chief executive officer of Sanara MedTech Inc., which has about 108 employees.

Has SMTI ever split its stock?

Yes. The most recent SMTI stock split was a 1-for-100 split on May 10, 2019, one of 2 splits on record.

What is the SMTI 52-week high?

The 52-week high for SMTI is $35.52 and the 52-week low is $16.05. The stock is currently 8.4% below its high.

Compare SMTI